Glimepiride 1/2/4 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Type 2 Diabetes Mellitus

• Canagliflozin
• Dapagliflozin
• Dulaglutide
• Empagliflozin
• Glipizide
• Insulin Glargine
• Metformin
• Pioglitazone

What Glimepiride 1/2/4 mg tabs is approved for (FDA label)

Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1)] . Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1) . Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: June 22, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Glimepiride 1/2/4 mg tabs (FDA label)

Glimepiride is formulated as tablets of: 1 mg (pink colored, flat-faced, oblong uncoated tablets with notched sides at double bisect, debossed with “X” and “76” on either side of the bisect on one face and plain on the other face) 2 mg (light green to green colored, flat-faced, oblong uncoated tablets with notched sides at double bisect, debossed with “Y” and “32” on either side of the bisect on one face and plain on the other face) 4 mg (light blue to blue colored, flat-faced, oblong uncoated tablets with notched sides at double bisect, debossed with “Y” and “34” on either side of the bisect on one face and plain on the other face) Tablets (scored): 1 mg, 2 mg, and 4 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: fc9d8495-184c-3af1-e053-6394a90a5e29. SPL document ID: 54de0888-3d86-7a85-e063-6394a90ab30d. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Glimepiride 1/2/4 mg tabs (FDA label)

The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling: Hypoglycemia [see Warnings and Precautions (5.1) ] Hemolytic anemia [see Warnings and Precautions (5.3) ] Common adverse reactions in clinical trials (≥5% and more common than with placebo) include hypoglycemia, headache, nausea, and dizziness (6.1) . To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1(844) 874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Approximately 2,800 patients with type 2 diabetes have been treated with glimepiride in the controlled clinical trials. In these trials, approximately 1,700 patients were treated with glimepiride for at least 1 year. In clinical trials, the most common adverse reactions with glimepiride were hypoglycemia, dizziness, asthenia, headache, and nausea.

Source: FDA prescribing information (DailyMed). Set ID: fc9d8495-184c-3af1-e053-6394a90a5e29. SPL document ID: 54de0888-3d86-7a85-e063-6394a90ab30d. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Glimepiride 1/2/4 mg tabs (FDA label)

Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: Glimepiride or any of the product’s ingredients [see Warnings and Precautions (5.2) ]. Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. Hypersensitivity to glimepiride or any of the product’s ingredients (4) Hypersensitivity to sulfonamide derivatives (4)

Source: FDA prescribing information (DailyMed). Set ID: fc9d8495-184c-3af1-e053-6394a90a5e29. SPL document ID: 54de0888-3d86-7a85-e063-6394a90ab30d. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Glimepiride 1/2/4 mg tabs (FDA label)

Hypoglycemia: May be severe. Ensure proper patient selection, dosing, and instructions, particularly in at-risk populations (e.g., elderly, renally impaired) and when used with other anti-diabetic medications. (5.1) Hypersensitivity Reactions: Postmarketing reports include anaphylaxis, angioedema and Stevens-Johnson syndrome. If a reaction is suspected, promptly discontinue glimepiride, assess for other potential causes for the reaction, and institute alternative treatment for diabetes. (5.2) Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase (G6PD) deficient. Consider a non-sulfonylurea alternative. (5.3) Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alternatives. (5.4) Macrovascular Outcomes: No clinical studies establishing conclusive evidence of macrovascular risk reduction with glimepiride or any other anti-diabetic drug. (5.5) 5.1 Hypoglycemia All sulfonylureas, including glimepiride, can cause severe hypoglycemia [see Adverse Reactions (6.1) ] . The patient’s ability to concentrate and react may be impaired as a result of hypoglycemia.

Source: FDA prescribing information (DailyMed). Set ID: fc9d8495-184c-3af1-e053-6394a90a5e29. SPL document ID: 54de0888-3d86-7a85-e063-6394a90ab30d. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Glimepiride 1/2/4 mg tabs (FDA label)

Certain medications may affect glucose metabolism, requiring glimepiride dose adjustment and close monitoring of blood glucose. (7.1) Miconazole: Severe hypoglycemia can occur when glimepiride and oral miconazole are used concomitantly. (7.2) Cytochrome P450 2C9 interactions: Inhibitors and inducers of cytochrome P450 2C9 may affect glycemic control by altering glimepiride plasma concentrations. (7.3) Colesevelam: Coadministration may reduce glimepiride absorption. Glimepiride should be administered at least 4 hours prior to colesevelam. (2.1, 7.4) 7.1 Drugs Affecting Glucose Metabolism A number of medications affect glucose metabolism and may require glimepiride dose adjustment and particularly close monitoring for hypoglycemia or worsening glycemic control.

Source: FDA prescribing information (DailyMed). Set ID: fc9d8495-184c-3af1-e053-6394a90a5e29. SPL document ID: 54de0888-3d86-7a85-e063-6394a90ab30d. Label effective date: June 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.